Eisbach is a clinical-stage biotechnology company based in Martinsried, Germany, focused on precision oncology. It develops allosteric drugs and uses its proprietary ALLOS discovery platform to target molecular machines involved in tumor genome reorganization and exploit synthetic lethality in defined tumors. The company's lead candidate, EIS-12656, is described as a first-in-class small molecule that shuts down the molecular process that reorganizes the tumor genome upon DNA damage and PARP activation. EIS-12656 demonstrated promising preclinical activity and an exceptional safety profile according to the company. Eisbach plans a Phase 1/2 clinical trial of EIS-12656 to be conducted at MD Anderson. The company recently received $4.5M from Cancer Focus Fund to support that clinical program. Eisbach Bio develops novel allosteric inhibitors that disrupt molecular machines involved in disease, with programs in oncology and antivirals. The company identified synthetic‑lethal and oncogenic helicases as cancer targets and has a SARS‑CoV‑2 Nsp13 helicase inhibitor as its COVID‑19 therapeutic candidate. Eisbach completed preclinical development of the antiviral and is progressing IND‑enabling work. The company received EUR 8 million in government funding to support clinical development through Phase I/II. It expects to initiate Phase I clinical trials for the COVID‑19 asset in Q1 2022. Eisbach was founded in 2019, is privately held, and is backed by international investors.

Total raised

$14M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2024